Roche's CAPP buy helps cancer drug development
This article was originally published in Scrip
A new acquisition by Roche in the field of liquid biopsy stands to bolster the company's anticancer R&D. Roche has expanded its presence in the space by buying CAPP Medical, a Palo Alto, California-based company that has developed technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in the blood.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.